Fibroblast Growth Factor Receptor (FGFR) Inhibitor Rogaratinib in Patients With Advanced Pretreated Squamous-cell Non-small Cell Lung Cancer (SQCLC) Overexpressing FGFR mRNA. A Multicenter, Single Arm Phase II Trial
Phase of Trial: Phase II
Latest Information Update: 12 Aug 2019
Price : $35 *
At a glance
- Drugs Rogaratinib (Primary)
- Indications Non-small cell lung cancer; Squamous cell cancer
- Focus Therapeutic Use
- 11 Jul 2019 Planned initiation date (estimated date for recruitment of the first subject) changed from 1 Jun 2019 to 1 Jul 2019.
- 03 Jun 2019 Status changed from not yet recruiting to recruiting.
- 20 May 2019 Planned initiation date changed from 1 Apr 2019 to 1 Jun 2019.